Blastic Plasmacytoid Dendritic Cell Neoplasm in Korean Population. (KBPDCN)

Samsung Medical Center

Status: Completed

Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm

Study type: Observational

Funder types: Other

Identifiers

NCT03974971

2019-02-035

Details and patient eligibility

About

Retrospective study , To analyze the clinical features and treatment outcomes in Korean blastic plasmacytoid dendritic cell neoplasm.

Full description

Blastic plasmacytoid dendritic cell neoplasm (BPDCN), with a synonym of blastic NK-cell lymphoma, agranular CD4+ natural killer cell leukaemia, blastic natural killer leukaemia/lymphoma, and agranular CD4+CD56+ haematodermic neoplasm/tumour, has been classified under "acute myeloid leukemia (AML) and related precursor neoplasms" since 2008 according to the World Health Organization (WHO) classification and among "myeloid neoplasm and acute leukemia" following 2016 revision of WHO classification. The plasmacytoid dendritic cells originates professional type I interferon-producing cells or plasmacytoid monocytes. Therefore, the prerequisite for diagnosis of BPDCN is the CD4+ and CD 56+ co-expression without common lymphoid or myeloid lineage markers1,2. This rare type of malignancy affecting predominantly elderly man, is reported to comprise 0.44% of hematologic malignancy3 and 0.7% of cutaneous lymphomas4, and the leukemic presentation or transformation is observed at initial presentation or even in the course of disease progression5.

Skin in¬volvement is a predominant clinical feature of BPDCN ranging in appearance from small bruise-like areas to patches, nodules, and ulcerated masses, but lymphadenopathy, splenomegaly, hepatomegaly are also commonly observed. There is no definite treatment guideline for BPDCN. Retrospective studies including acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL)/lymphoma-like chemotherapy for management of BPDCN reported 53-89% of high complete remission rates but an eventual very poor overall survival of 12-23 months, with a preponderance of ALL/lymphoma- over AML-like treatment5. Recently, targeted therapy with SL401, an IL-3 fusion protein which binds to CD123, is promising and the results of the clinical trial will be unveiled in the near future6.

Although several retrospective and small case series has been published so far7,8, there is still no multicenter study on BPDCN classified after 2008 WHO classification in Asian population. This study aims to retrospectively collect data of BPDCN patients from centers participating the Consortium for improving survival of lymphoma (CISL) and analyze the clinical features and treatment outcomes in this rare type of hematologic malignancy.

Enrollment: 36 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

<Inclusion Criteria>

1. Patients ≥ 18 years

2. Pathologically confirmed diagnosis by tissue or bone marrow at each center with

   • Blastic plasmacytoid dendritic cell neoplasm
   • Blastic NK-cell lymphoma
   • Agranular CD4+ natural killer cell leukaemia
   • Blastic natural killer leukaemia/lymphoma
   • Agranular CD4+CD56+ haematodermic neoplasm/tumour

3. Antigen expression of CD4 and/or CD56 coupled with at least one plasmacytoid dendritic cell-associated antigen among CD123, TCL1, CD2AP and BDCA2/CD303

<Exclusion Criteria>

1. Acute myeloid leukemia
2. Acute lymphoblastic leukemia
3. Mixed phenotype acute leukemia
4. Any type of B- or T-/NK/T-cell lymphomas
5. Expression of lineage-specific markers for B cells (CD20, CD79a) T cells (CD3) Myeloid cells (myeloperoxidase) Monocytes (CD11c, CD163, lysozyme). CD34

Trial design

36 participants in 1 patient group

BPDCN diagnosis group

Description:

By review medical records Enroll patients diagnosed with BPDCN from January 1, 2000 to October 31, 2018